Sign in

You're signed outSign in or to get full access.

Matt Sik

Research Analyst at Goldman Sachs Group Inc.

There is no publicly available record of Matt Sik working as an analyst at Goldman Sachs, nor any LinkedIn profile confirming this identity or professional history. After searching across major professional and financial directories, no evidence could be found regarding Matt Sik’s job title, coverage universe, career timeline, performance metrics, or recognized credentials in the financial industry.

Matt Sik's questions to MYRIAD GENETICS (MYGN) leadership

Question · Q1 2025

Matt Sik of Goldman Sachs asked for more specifics on the sources of the $25 million in operating expense reductions in the revised guidance. He also inquired about the remaining potential for improvement in Revenue Cycle Management (RCM).

Answer

CEO Samraat Raha and CFO Scott Leffler explained that OpEx savings are being realized from discretionary areas like hiring controls, travel, and consulting fees, while protecting strategic investments in R&D and commercial operations. Regarding RCM, Scott Leffler noted that despite improving the no-pay rate in 2024, a significant opportunity remains to capture revenue from the large volume of unpaid claims, and investments in this area continue.

Ask follow-up questions

Fintool

Fintool can predict MYRIAD GENETICS logo MYGN's earnings beat/miss a week before the call